Secondary prevention of renal and cardiovascular disease: Results of a renal and cardiovascular treatment program in an Australian Aboriginal community

• Published in: Journal of the American Society of Nephrology Vol. 14; no. 7 Suppl 2; pp. S178 - S185
• Main Authors: HOY, Wendy E, ZHIQIANG WANG, BAKER, Philip R. A, KELLY, Angela M
• Format: Conference Proceeding Journal Article
• Language: English
• Published: Hagerstown, MD Lippincott Williams & Wilkins 01-07-2003
• Subjects: Adolescent; Adult; Age Distribution; Aged; Antihypertensive Agents - therapeutic use; Australia; Biological and medical sciences; Cardiovascular Diseases - ethnology; Cardiovascular Diseases - prevention & control; Female; Humans; Hypertension - diagnosis; Hypertension - drug therapy; Hypertension - ethnology; Incidence; Kidney Failure, Chronic - ethnology; Kidney Failure, Chronic - prevention & control; Kidneys; Male; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; Oceanic Ancestry Group; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Sex Distribution; Survival Analysis; Treatment Outcome; Urinary system involvement in other diseases. Miscellaneous; Australia; Oceania; Human; Prevention; Kidney disease; Secondary; Urinary system disease; Treatment; Aboriginal; Cardiovascular disease; Public health
• ISSN: 1046-6673; 1533-3450
• DOI: 10.1097/01.ASN.0000070033.86955.48

Australian Aborigines are experiencing an epidemic of renal and cardiovascular disease. In late 1995 we introduced a treatment program into the Tiwi community, which has a three- to fivefold increase in death rates and a recent annual incidence of treated ESRD of 2760 per million. Eligible for treatment were people with hypertension, diabetics with micro or overt albuminuria, and all people with overt albuminuria. Treatment centered around use of perindopril (Coversyl, Servier), with other agents added to reach BP goals; attempts to control glucose and lipid levels; and health education. Thirty percent of the adult population, or 267 people, were enrolled, with a mean follow up of 3.39 yr. Clinical parameters were followed every 6 mo, and rates of terminal endpoints were compared with those of 327 historical controls matched for baseline disease severity, followed in the pretreatment program era. There was a dramatic reduction in BP in the treatment group, which was sustained through 3 yr of treatment. Albuminuria and GFR stabilized or improved. Rates of natural deaths were reduced by an estimated 50% (P = 0.012); renal deaths were reduced by 57% (P = 0.038); and nonrenal deaths by 46% (P = 0.085). Survival benefit was suggested at all levels of overt albuminuria, and regardless of diabetes status, baseline BP, or prior administration of angiotensin converting enzyme inhibitors (ACEI). No significant benefit was apparent among people without overt albuminuria, nor among those with GFR less than 60 ml/min. An estimated 13 renal deaths and 10 nonrenal deaths were prevented, with the number-needed-to-treat to avoid one terminal event of only 11.6. Falling deaths and renal failure in the whole community support these estimates. The program was extremely cost-effective. Programs like this should be introduced to all high-risk communities as a matter of urgency.